Mepact
·
- Prescription status not stated
- Cancer treatments and immune-system medicines
- Active substance
- Mifamurtide
- Made by
- Esteve Pharmaceuticals, S.A.
- Source
- Official label
Quoted from the official source. Not yet reviewed by Mediclarum — the leaflet in your pack is authoritative.
What it is for
- Mepact is indicated in children, adolescents and young adults for the treatment of high-grade resectable non-metastatic osteosarcoma after macroscopically complete surgical resection. It is used in combination with postoperative multi-agent chemotherapy. Safety and efficacy have been assessed in studies of patients two to 30 years of age at initial diagnosis.
From the official label · 2026-09-30 · European Medicines Agency
Same active substance, strength and form in other countries
Matched on active substance, strength and kind of form only. This is not a statement that the products are equivalent or interchangeable: other ingredients, release and approved uses can differ — ask a pharmacist before swapping.
Medicine passport: one printable page to show a pharmacist abroad
SpainNo exact match for this strength and form
NetherlandsNo exact match for this strength and form
Details
| Made by | Esteve Pharmaceuticals, S.A. |
|---|---|
| Active substance | Mifamurtide |
| Used in | Cancer treatments and immune-system medicines |
| Classification | L03AX15 · Cancer treatments and immune-system medicines |
| Authorised on | 2009-03-06 |
| Last updated by the regulator | 2026-09-16 |
| EMA product number | EMEA/H/C/000802 |
Source: European Medicines Agency — medicine data · 2026-09-30 · not reviewed by a clinician
Source: European Medicines Agency (EMA). Product information as published by EMA. Reuse terms: EMA legal notice (reproduction authorised).